1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Two: Mid-Table Movements See Firms Jostle For Position

Some Companies Climb As Others Slip Down Rankings

 
• By Dave Wallace

Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.

Generics Bulletin Top 50 2022
Mid-table companies have moved in various directions • Source: Shutterstock

With the significant movements seen among the 10 leading companies in Generics Bulletin’s Top 50 this year nevertheless leaving the ranking order of firms at the very top of that top-10 table undisturbed, a similar trend can be observed in the second part of our rundown, covering positions 11-30. (Also see "The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations" - Generics Bulletin, 15 August, 2022.)

Compared to last year, the same five companies lead off this second table, in the same order – with Cipla,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2025

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

The Generics Bulletin Top 50, Part Two: Leading Players Leapfrog The Competition

 
• By Dave Wallace

In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

 
• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

UK Sitagliptin Prices Shoot Up In June

 
• By Dave Wallace

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

UK Pioglitazone Prices Go Through The Roof Among A Raft Of May Rises

 
• By Dave Wallace

As multiple molecules experienced triple-digit percentage price rises in May, pioglitazone once again led the way after already topping our table of price increases in April.

Pioglitazone Prices Peak In April As Multiple UK Molecules Double In Price

 
• By Dave Wallace

Diabetes medication pioglitazone topped the list of the fastest-rising UK generics prices in April, according to market researcher WaveData.